Bethesda, MD – According to filings with the U.S. Securities and Exchange Commission, Gain Therapeutics is raising $10,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Eric Richman played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Gain Therapeutics

Gain Therapeutics SA is a preclinical biotech company specializing in the discovery of new drugs for rare and CNS diseases. The company targets lysosomal enzymes to develop innovative drugs for rare pediatric genetic disorders and selected CNS diseases with high unmet medical needs. Gain Therapeutics SA is developing a new class of compounds: structurally targeted allosteric regulators, identified through its pioneering proprietary platform, SEE-Tx.

To learn more about Gain Therapeutics, visit http://www.gaintherapeutics.com/

Contact:
Eric Richman, Chief Executive Officer
301-500-1556
https://www.linkedin.com/in/eric-richman-516b79/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved